Ich stimme zu, dass diese Seite Cookies verwende. Weitere Informationen finden Sie unter unseren Datenschutzerklärungen .
X
Duras, J.
618  Ergebnisse:
Personensuche X
?
1

Strategically Developed Strong Red‐Emitting Oxyfluoride Nan..:

Abraham, Malini ; Thejas, K. K. ; Kunti, Arup K....
Advanced Optical Materials.  , 2024
Link: https://doi.org/10.1002/..
 
?
2

ANALYSIS OF PATIENTS IN THE FIRST RELAPSE OR PROGRESSION OF..:

Janikova, A. ; Belada, D. ; Klanova, M....
Hematological Oncology.  41 (2023)  S2 - p. 764-764 , 2023
Link: https://doi.org/10.1002/..
 
?
3

HOW WE ARE SUCCESSFUL IN THERAPY OF T‐CELL LYMPHOMA PATIENT..:

Janikova, A. ; Klanova, M. ; Belada, D....
Hematological Oncology.  41 (2023)  S2 - p. 762-762 , 2023
Link: https://doi.org/10.1002/..
 
?
4

BRENTUXIMAB VEDOTIN IN COMBINATION WITH CHEMOTHERAPY IN PAT..:

Klanova, M. ; Sykorova, A. ; Janikova, A....
Hematological Oncology.  41 (2023)  S2 - p. 763-764 , 2023
Link: https://doi.org/10.1002/..
 
?
5

OUTCOMES OF THE TREATMENT AFTER ANTI‐CD19 CAR‐T THERAPY FAI..:

Sýkorová, A. ; Polgárová, K. ; Folber, F....
Hematological Oncology.  41 (2023)  S2 - p. 792-793 , 2023
Link: https://doi.org/10.1002/..
 
?
6

Clinical value of ALK and CD30 expression in mature systemi..:

Janikova, A. ; Michalka, J. ; Chloupkova, R....
Annals of Hematology.  101 (2022)  4 - p. 789-798 , 2022
Link: https://doi.org/10.1007/..
 
?
7

P1104: A PHASE 1 STUDY EVALUATING SAFETY AND EFFICACY OF PA..:

Hamadani, M. ; Coleman, M. ; Boccia, R....
HemaSphere.  6 (2022)  - p. 994-995 , 2022
Link: https://doi.org/10.1097/..
 
?
8

PERIPHERAL T‐CELL LYMPHOMAS INVOLVING CENTRAL NERVOUS SYSTE..:

Mocikova, H. ; Pytlik, R. ; Benesova, K....
Hematological Oncology.  39 (2021)  S2 - p. , 2021
Link: https://doi.org/10.1002/..
 
?
9

POLATUZUMAB VEDOTIN PLUS BENDAMUSTINE AND RITUXIMAB IN PATI..:

Vodicka, P ; Benesova, K ; Janikova, A...
Hematological Oncology.  39 (2021)  S2 - p. , 2021
Link: https://doi.org/10.1002/..
 
?
10

CHARACTERIZATION OF DUVELISIB IN PATIENTS WITH REFRACTORY M..:

Jacobsen, E. ; Ďuraš, J. ; Ardeshna, K....
Hematological Oncology.  37 (2019)  S2 - p. 400-401 , 2019
Link: https://doi.org/10.1002/..
 
?
11

T‐CELL LYMPHOMA IN THE ELDERLY PATIENTS. WHO IS YOUNG, OLD,..:

Janikova, A. ; Chloupkova, R. ; Klener, P....
Hematological Oncology.  37 (2019)  S2 - p. 465-467 , 2019
Link: https://doi.org/10.1002/..
 
?
12

IS IT RADIOTHERAPY NECESSARY FOR PRIMARY MEDIASTINAL B‐CELL..:

Trneny, M. ; Polgarova, K. ; Janikova, A....
Hematological Oncology.  37 (2019)  S2 - p. 267-268 , 2019
Link: https://doi.org/10.1002/..
 
?
13

DA‐EPOCH‐R VERSUS R‐CHOP IN HIGH RISK DLBCL PATIENTS: ANALY..:

Šimkovič, M. ; Móciková, H. ; Ďuraš, J....
Hematological Oncology.  37 (2019)  S2 - p. 433-434 , 2019
Link: https://doi.org/10.1002/..
 
?
14

PREDICTIVE VALUE OF PRIMA‐PROGNOSTIC INDEX (PRIMA‐PI) IN FI..:

Ďuraš, J. ; Procházka, V. ; Belada, D....
Hematological Oncology.  37 (2019)  S2 - p. 398-399 , 2019
Link: https://doi.org/10.1002/..
 
?
15

PROGNOSTIC VALUE OF THE INTERVAL BETWEEN RELAPSE AND THERAP..:

Janikova, A. ; Chloupkova, R. ; Campr, V....
Hematological Oncology.  37 (2019)  S2 - p. 413-414 , 2019
Link: https://doi.org/10.1002/..
 
1-15